NRIX
Nurix Therapeutics
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
News
- Nurix Therapeutics enrolls the first patient in a Phase 1b/2 combination study of bexobrutideg in chronic lymphocytic leukemiaOct 7, 2026
- Nurix Therapeutics announces a second extension of the research term for its oncology program under the Gilead Sciences collaborationOct 5, 2026
- Nurix Therapeutics presents preclinical data from novel IRAK4 degrader, GS-6791, demonstrating potent inhibition of IL-1 and IL-36 in vitro and efficacy in dermatitis modelSep 17, 2025
- EMA grants orphan drug designation to Bexobrutideg (NX-5948) for lymphoplasmacytic lymphoma (Waldenström macroglobulinemia)Jul 10, 2025
- Nurix shows updated data for Bexobrutideg in relapsed/refractory CLL and WM with sustained deepening responsesJun 12, 2025